Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas (Q38627352)

4 September 2017

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas (English)

1 reference

4 September 2017

1

1 reference

PubMed ID

26545844

Alexandra Traverse-Glehen

4 September 2017

series ordinal

2

object named as

Alexandra Traverse-Glehen

1 reference

4 September 2017

3

Bertrand Coiffier

1 reference

4 September 2017

1 November 2015

1 reference

Lancet Oncology Commission

4 September 2017

1 reference

4 September 2017

16

1 reference

4 September 2017

e555-67

1 reference

4 September 2017

15

1 reference

Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Double-hit B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Reflecting on 25 years with MYC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MYC on the path to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Translocations involving c-myc and c-myc function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

A clinician's guide to double hit lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Bromodomain inhibition in diffuse large B-cell lymphoma--giving MYC a brake.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900005-4

7 January 2021

10.1016/S1470-2045(15)00005-4

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26545844